Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA approves Q-Med's Deflux for VUR (vesicoureteral reflux):

This article was originally published in Clinica

Executive Summary

The US FDA has approved for sale Q-Med's injectable Deflux implant for treating vesicoureteral reflux (VUR) in children. VUR is a condition that leads to urine leakage from the urinary bladder back into the kidneys and which can, in the long-term, result in irreversible kidney damage. Consisting of NASHA (non-animal stabilised hyaluronic acid) and dextranomer, Deflux is the first endoscopic treatment for VUR to be approved by the FDA, claims Q-Med, of Uppsala, Sweden. The firm estimates that the US market for the product is worth $30 million annually. Deflux is already sold in over 10 markets, mainly in Europe.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts